Multiple myeloma – from pathogenesis to modern therapy
Authors:
Si. Ševčíková 1; T. Růžičková 1,2; M. Jarošová 2; L. Pour 2; Sa. Ševčíková 1,2
Authors‘ workplace:
Babákova myelomová skupina, Ústav patologické fyziologie, LF MU, Brno
1; Interní hematologická a onkologická klinika FN Brno
2
Published in:
Transfuze Hematol. dnes,32, 2026, No. 3, p. 190-196.
Category:
Review/Educational Papers
doi:
https://doi.org/10.48095/cctahd202621
Overview
Multiple myeloma (MM) is the second most common haematological malignancy, characterized by the clonal proliferation of plasma cells in the bone marrow and the production of monoclonal immunoglobulin. The disease causes organ damage defined by the CRAB criteria (hypercalcemia, renal failure, anaemia, and bone lesions). Due to the influence of modern medicine, MM is transforming from an acute to a chronic disease, with the primary goal being the achievement of long-term minimal residual disease negativity. This article provides a comprehensive overview of the evolution of diagnostic and classification criteria, the genetic heterogeneity of the disease, and innovative therapeutic approaches.
Keywords:
Multiple myeloma – monoclonal gammopathy – minimal residual disease – multiple myeloma therapy
Sources
1. Kyle RA, Durie BGM, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010; 24 : 1121–1127. doi: 10.1038/leu.2010.60.
2. Sandecká V, Hájek R, Pour L, et al. A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. Eur J Haematol. 2017; 99 : 80–90. doi: 10.1111/ejh.12894.
3. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15: e538–e548. doi: 10.1016/S1470-2045 (14) 70442-5.
4. Maluskova D, Svobodová I, Kucerova M, et al. Epidemiologie mnohočetného myelomu v České republice. Klin Onkol. 2017; 30 : 35–42. doi: 10.14735/amko20172S35.
5. Hájek R, Maisnar V, Minařík J, et al. Diagnostika a léčba mnohočetného myelomu 2023. Doporučení České myelomové skupiny, Slovenské myelómové skupiny a Myelomové sekce České hematologické společnosti pro diagnostiku a léčbu mnohočetného myelomu. Transfuze Hematol Dnes. 2023; 29 (Suppl 2): 2S7–2S134.
6. Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia. 2017; 31 : 1915–1921. doi: 10.1038/leu.2016.380.
7. Dimopoulos MA, Ntanasis-Stathopoulos I, Fotiou D, et al. Determinants of 15-year progression-free survival in multiple myeloma; real-world data from a single institution. Am J Hematol. 2025; 100 : 1747–1759. doi: 10.1002/ ajh.70012.
8. Ščudla V, Minařík J, Bačovský J, et al. Změna prognózy nemocných s mnohočetným myelomem v průběhu 60 let v souboru 1 492 neselektovaných nemocných z oblasti střední a zčásti i severní Moravy. Transfuze Hematol Dnes. 2026; 32 (2): 105-125. doi: 10.48095/cctah d202612.
9. Arroz M, Came N, Lin P, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016; 90 : 31–39. doi: 10.1002/ cyto.b.21228.
10. Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005; 23 : 3412–3420. doi: 10.1200/JCO.2005.04.242.
11. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015; 33 : 2863–9. doi: 10.1200/JCO.2015.61.2267
12. D’Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022; 40 : 3406–3418. doi: 10.1200/JCO.21.02614.
13. Avet-Loiseau H, Davies FE, Samur MK, et al. International Myeloma Society/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. J Clin Oncol. 2025; 43 : 2739–2751. doi: 10.1200/JCO-24-01893.
14. Smetana J, Dementyeva E, Kryukov F, et al. Incidence of cytogenetic aberrations in two B lineage subpopulations in multiple myeloma patients analyzed by combination of whole-genome profiling and FISH. Neoplasma. 2014; 61 : 48–55.
15. Bong IPN, Esa E. Molecular genetic aberrations in the pathogenesis of multiple myeloma. Asian Biomed (Res Rev News). 2023; 17 : 152–162. doi: 10.2478/abm-2023-0056.
16. Clarke SE, Fuller KA, Erber WN. Chromosomal defects in multiple myeloma. Blood Rev. 2024; 64 : 101168. doi: 10.1016/j.blre.2024. 101168.
17. Besse L, Sedlarikova L, Greslikova H, et al. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol. 2016; 97 : 93–100. doi: 10.1111/ejh.12688.
18. Manier S, Salem K, Glavey SV, et al. Genomic aberrations in multiple myeloma. Cancer Treat Res. 2016; 169 : 23–34. doi: 10.1007/978-3-319-40320-5_3.
19. Holland AJ, Cleveland DW. Chromoanagenesis and cancer: mechanisms and consequences of localized, complex chromosomal rearrangements. Nat Med. 2012; 18 : 1630–1638. doi: 10.1038/nm.2988.
20. Pellestor F. Chromoanagenesis: cataclysms behind complex chromosomal rearrangements. Mol Cytogenet. 2019; 12 : 6. doi: 10.1186/s13 039-019-0415-7.
21. Lee KJ, Lee KH, Yoon K-A, et al. Chromothripsis in treatment resistance in multiple myeloma. Genomics Inform. 2017; 15 : 87–97. doi: 10.5808/GI.2017.15.3.87.
22. Rustad EH, Yellapantula VD, Glodzik D, et al. Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov. 2020; 1 : 258–273. doi: 10.1158/2643-3230.BCD-20-0132.
23. Liu P, Erez A, Nagamani SCS, et al. Chromosome catastrophes involve replication mechanisms generating complex genomic rearrangements. Cell. 2011; 146 : 889–903. doi: 10.1016/j.cell.2011.07.042.
24. Nižňanská D, Ševčíková S, Vlachová M, et al. Molekulární podstata mnohočetného myelomu. Klin Onkol. 2024; 37 (1): 27–33. doi: 10.48095/ccko202427.
25. Kyle RA, Steensma DP. History of multiple myeloma. Recent Results Cancer Res. 2011; 183 : 3–23. doi: 10.1007/978-3-540-85772-3_1.
26. Holland JR, Hosley H, Scharlau C, et al. A controlled trial of urethane treatment in multiple myeloma. Blood. 1966; 27 : 328–342.
27. Blokhin N, Larionov L, Perevodchikova N, et al. Clinical experiences with sarcolysin in neoplastic diseases. Ann N Y Acad Sci. 1958; 68 : 1128–1132. doi: 10.1111/j.1749-6632.1958.tb42675.x.
28. Mass RE. A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother Rep. 1962; 16 : 257–259.
29. Harley JB, Pajak TF, McIntyre OR, et al. Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. Blood. 1979; 54 : 13–22.
30. Larkin M. Low-dose thalidomide seems to be effective in multiple myeloma. Lancet. 1999; 354 : 925. doi: 10.1016/S0140-6736 (05) 75677-4.
31. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002; 100 : 3063–3067. doi: 10.1182/blood-2002-03-0996.
32. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004; 22 : 3269–3276. doi: 10.1200/JCO.2004.10.052.
33. Charliński G, Vesole DH, Jurczyszyn A. Rapid progress in the use of immunomodulatory drugs and cereblon E3 ligase modulators in the treatment of multiple myeloma. Cancers (Basel). 2021; 13 : 4666. doi: 10.3390/cancers13184666.
34. Morgan GJ, Davies FE. Role of thalidomide in the treatment of patients with multiple myeloma. Crit Rev Oncol Hematol. 2013; 88 (Suppl 1): S14–S22. doi: 10.1016/j.critrevonc.2013.05.012.
35. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002; 20 : 4420–4427. doi: 10.1200/JCO.2002.01.133.
36. Sandecká V, Pour L, Špička I, et al. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. Eur J Haematol. 2021; 107 : 466–474. doi: 10.1111/ejh.13683.
37. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007; 67 : 6383–6391. doi: 10.1158/0008-5472.CAN-06-4086.
38. Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011; 17 : 5311–5321. doi: 10.1158/1078-0432.CCR-11-0476.
39. de Weers M, Tai Y-T, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011; 186 : 1840–1848. doi: 10.4049/jimmunol.1003032.
40. Deckert J, Wetzel M-C, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014; 20 : 4574–4583. doi: 10.1158/1078-0432.CCR-14-0695.
41. Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384 : 705–716. doi: 10.1056/NEJMoa2024850.
42. Davenport AJ, Cross RS, Watson KA, et al. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc Natl Acad Sci U S A. 2018; 115: E2068–E2076. doi: 10.1073/pnas. 1716266115.
43. Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022; 387 : 495–505. doi: 10.1056/NEJMoa2203478.
44. Zhou X, Luo E, Chen W, et al. The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma. Front Med (Lausanne). 2025; 12 : 1593405. doi: 10.3389/fmed.2025.1593405.
45. Heestermans R, Schots R, De Becker A, et al. Liquid biopsies as non-invasive tools for mutation profiling in multiple myeloma: application potential, challenges, and opportunities. Int J Mol Sci. 2024; 25 : 5208. doi: 10.3390/ijms 25105208.
46. Vlachová M, Pečinka L, Gregorová J, et al. Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients. Sci Rep. 2024; 14 : 18777. doi: 10.1038/s41598-024-69408-1.
47. Jelinek T, Bezdekova R, Zihala D, et al. More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma. J Clin Oncol. 2023; 41 : 1383–1392. doi: 10.1200/JCO.22.01226.
48. Costa LJ, Chhabra S, Medvedova E, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023; 10: e890–e901. doi: 10.1016/S2352-3026 (23) 00236-3.
49. Ferla V, Antonini E, Perini T, et al. Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy. Front Oncol. 2022; 12 : 932852. doi: 10.3389/fonc.2022.932852.
50. Mateos M-V, Nooka AK, Larson SM. Moving toward a cure for myeloma. Am Soc Clin Oncol Educ Book. 2022; 42 : 1–12. doi: 10.1200/EDBK_349603.
51. San-Miguel JF, Mateos M-V. Can multiple myeloma become a curable disease? Haematologica. 2011; 96 : 1246–1248. doi: 10.3324/haematol.2011.051169.
52. Landgren O, Kazandjian D. Modern myeloma therapy + sustained minimal residual disease-negative = (functional) cure! J Clin Oncol. 2022; 40 : 2863–2866. doi: 10.1200/JCO.22.00622.
53. Kitundu JH. Redefining cure in multiple myeloma: are we chasing a moving target? Health Sci Rep. 2025; 8: e71581. doi: 10.1002/hsr2.71581.
54. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024; 390 : 301–313. doi: 10.1056/NEJMoa2312054.
55. Nooka AK, Cohen AD, Lee HC, et al. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. Cancer. 2023; 129 : 3746–3760. doi: 10.1002/cncr.34987.
56. Research C for BE and. FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. FDA. Published Online First: 28 November 2023. https: //www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous
57. Liu E, Marin D, Banerjee P, et al. Use of CAR-Transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020; 382 : 545–553. doi: 10.1056/NEJMoa1910607.
58. Grab AL, Kim PS, John L, et al. Pre-clinical assessment of SAR442257, a CD38/CD3xCD28 trispecific T cell engager in treatment of relapsed/refractory multiple myeloma. Cells. 2024; 13 : 879. doi: 10.3390/cells13100879.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2026 Issue 3
- Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Prognostic Significance of Subclinical Joint Changes on MRI in Hemophilia
- Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy
- Minimum and Optimal Factor Levels in Physically Active Hemophiliacs
Most read in this issue
- Targeted treatment approaches for mantle cell lymphoma
- Multiple myeloma – from pathogenesis to modern therapy
- Emerging therapies for relapsed/refractory follicular lymphoma
- Evaluation of morphological changes in platelets during storage of platelet concentrates